23andMe Co-Founder Anne Wojcicki’s Net Worth After Bankruptcy

What Is Anne Wojcicki’s Net Worth?

Anne Wojcicki is an American entrepreneur, biotech analyst, and co-founder of the personal genomics company 23andMe. As of 2025, Anne Wojcicki has a net worth of $150 million. Once touted as one of the most visionary figures in the health-tech industry, Wojcicki saw her fortune soar—and later decline dramatically—alongside the rise and fall of 23andMe.

Though her company’s valuation once placed her paper net worth north of $500 million, 23andMe’s financial troubles and eventual bankruptcy in March 2025 sharply cut into her wealth. Nevertheless, Anne Wojcicki remains a pioneering figure in consumer genetics and one of Silicon Valley’s most fascinating personalities.

23andMe: From Disruption to Decline

Wojcicki co-founded 23andMe in 2006 with the goal of empowering consumers to understand their DNA through affordable, at-home genetic testing kits. The company was a game-changer, quickly gaining attention for its ancestry services and, later, health reports approved by the FDA.

Tanner Martin Announces His Death in Heartfelt Video After 5-Year Cancer Battle

In 2021, 23andMe merged with Richard Branson’s VG Acquisition Corp to become a public company. The deal raised nearly $600 million and initially valued the company at $3.5 billion. During its first year on the public markets, its valuation briefly peaked at $6 billion, giving Anne’s 9% ownership a theoretical value of around $540 million.

However, the hype was short-lived. Despite millions of users, 23andMe struggled to achieve profitability. The company went through multiple rounds of layoffs starting in 2022 and burned through a significant portion of its cash reserves. By early 2024, the stock had plummeted more than 99%, and NASDAQ threatened to delist it. On March 24, 2025, 23andMe filed for bankruptcy. Anne Wojcicki stepped down as CEO on the same day.

Ronnie McDowell Suffers Mini Stroke During Festival Performance, Recovering After Hospitalization

At the time of the bankruptcy filing, the company’s market cap had dwindled to just $20 million, and Anne’s remaining stake was worth an estimated $1.8 million—a stunning fall from its peak.

Early Life and Education

Anne E. Wojcicki was born on July 28, 1973, in Palo Alto, California, into a family of academics. Her father, Stanley, was a physics professor at Stanford, and her mother, Esther, is a renowned educator and journalist. Anne grew up on the Stanford campus alongside her two sisters: Susan Wojcicki, the former CEO of YouTube, and Janet Wojcicki, an epidemiologist.

Anne attended Yale University, where she majored in biology and played on the varsity women’s ice hockey team. After graduating in 1996, she conducted molecular biology research at the National Institutes of Health and the University of California, San Diego.

Bobby Sherman Family: Meet His Wife Brigitte, Sons, and Grandchildren

Career Beginnings and the Birth of 23andMe

Before launching 23andMe, Anne worked as a healthcare investment analyst for nearly four years. She became increasingly disillusioned with how the financial world approached health care—valuing short-term profits over long-term breakthroughs. In response, she pivoted to biotech entrepreneurship with a vision: give people direct access to their genetic data to inspire proactive health management.

23andMe’s personal genome service was revolutionary, winning Time magazine’s “Invention of the Year” in 2008. By 2015, the company began receiving FDA approval for health-related genetic testing, solidifying its role as a trailblazer in the direct-to-consumer health space.

In 2018, 23andMe struck a $300 million deal with GlaxoSmithKline, giving the pharmaceutical giant exclusive rights to mine the company’s massive genetic database to aid in drug development. While the deal sparked some controversy over privacy, it marked a major milestone for the company.

Anne consistently advocated for customer-driven research, often emphasizing the power of collective data to unlock medical breakthroughs.

Highs and Lows of a Public Company

The excitement surrounding 23andMe’s 2021 IPO was palpable. Anne became a high-profile public CEO, appearing on major media platforms and securing partnerships across tech and pharma. But despite early success, challenges mounted quickly. The company struggled to pivot from consumer testing to drug development and couldn’t sustain growth.

After multiple layoffs, plummeting stock prices, and mounting losses, 23andMe filed for bankruptcy in March 2025, with Anne stepping down as CEO—marking a humbling end to a company once considered the future of healthcare.

Personal Life

Anne Wojcicki was married to Google co-founder Sergey Brin from 2007 until their divorce in 2015. The two share two children and have remained amicable co-parents. Their union not only linked two powerful Silicon Valley figures but also helped fund early efforts at 23andMe—Google invested $3.9 million in the company in 2007.

After her divorce, Anne briefly dated Alex Rodriguez in 2016, making headlines as the two were frequently spotted together at high-profile events.

Anne and Sergey also co-managed the Brin Wojcicki Foundation, which has donated millions to causes such as Parkinson’s research, immigrant support, and Wikipedia.

Legacy and Outlook

Though 23andMe’s financial story ended in bankruptcy, Anne Wojcicki’s influence on personal genomics and health tech cannot be overstated. She pioneered the concept of consumer-driven health data, opened the door for FDA-approved at-home genetic testing, and helped spark important discussions around medical privacy and ethics.

While her fortune has shrunk from its once-lofty heights, Anne Wojcicki remains a respected voice in biotech and an influential figure in Silicon Valley. Whether she returns with a new venture or shifts to philanthropic efforts, her legacy as a biotech disruptor is firmly in place.